Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 AI patient education for thyroid and chronic conditions at $125M valuation Sep 2024; $22.2M from Google, Harvard endowment, Gaingels/YC competing with Paloma Health for AI-driven medical knowledge accessibility for underdiagnosed chronic disease.
Rejoy Health is a San Francisco-based AI-powered healthcare platform — backed by Y Combinator (W21) with $22.2 million in total funding from Y Combinator, Google, Gaingels, and the Harvard University endowment fund, achieving a $125 million valuation in September 2024 — providing patients with chronic conditions (particularly thyroid disorders) with AI-driven medical knowledge accessibility tools and subscription-based treatment and management services that bridge the gap between patient symptoms, lab results, and clinical recommendations. Founded in 2020 by former Facebook and Microsoft engineers and launched through Y Combinator, Rejoy translates complex medical information into personalized, understandable patient guidance using artificial intelligence.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.